Esperion Therapeutics (ESPR) PT Raised to $5 at Citizens After Q4 Results
Tweet Send to a Friend
Citizens analyst Jason N. Butler raised the price target on Esperion Therapeutics (NASDAQ: ESPR) to $5.00 (from $4.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
